| 1 | MAP2K1
|
| Somatic MAP2K1 Mutations Are Associated with Extracranial Arteriovenous Malformation.
|
| Couto JA, Huang AY, Konczyk DJ, Goss JA, Fishman SJ, Mulliken JB, Warman ML, Greene AK.
|
| Am J Hum Genet 100(3):546-554. doi: 10.1016/j.ajhg.2017.01.018. Epub 2017 Feb 9.
2017
|
| 2 | MAP2K1
|
| Inhibition of MEK1 Signaling Pathway in the Liver Ameliorates Insulin Resistance.
|
| Ueyama A, Ban N, Fukazawa M, Hirayama T, Takeda M, Yata T, Muramatsu H, Hoshino M, Yamamoto M, Matsuo M, Kawashima Y, Iwase T, Kitazawa T, Kushima Y, Yamada Y, Kawabe Y.
|
| J Diabetes Res 2016:8264830. doi: 10.1155/2016/8264830. Epub 2015 Dec 28.
2016
|
| 3 | IL10, IL12A, MAP2K1, TLR4
|
| MEK1 dependent and independent ERK activation regulates IL-10 and IL-12 production in bone marrow derived macrophages.
|
| Bouhamdan M, Bauerfeld C, Talreja J, Beuret L, Charron J, Samavati L.
|
| Cell Signal 27(10):2068-76. doi: 10.1016/j.cellsig.2015.07.015. Epub 2015 Jul 21.
2015
|
| 4 | MAP2K1, MAP2K2
|
| ERK1/2 can feedback-regulate cellular MEK1/2 levels.
|
| Hong SK, Wu PK, Karkhanis M, Park JI.
|
| Cell Signal 27(10):1939-48. doi: 10.1016/j.cellsig.2015.07.003. Epub 2015 Jul 9.
2015
|
| 5 | MAP2K1, MAPK3
|
| Regulation of ERK Kinase by MEK1 Kinase Inhibition in the Brain.
|
| Tassin TC, Benavides DR, Plattner F, Nishi A, Bibb JA.
|
| J Biol Chem 290(26):16319-29. doi: 10.1074/jbc.M115.654897. Epub 2015 May 13.
2015
|
| 6 | MAP2K1
|
| Regulation of the mitogen-activated protein kinase kinase (MEK)-1 by NAD(+)-dependent deacetylases.
|
| Yeung F, Ramsey CS, Popko-Scibor AE, Allison DF, Gray LG, Shin M, Kumar M, Li D, McCubrey JA, Mayo MW.
|
| Oncogene 34(6):798-804. doi: 10.1038/onc.2014.39. Epub 2014 Mar 31.
2015
|
| 7 | MAP2K1
|
| MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer.
|
| Pénzváltó Z, Lánczky A, Lénárt J, Meggyesházi N, Krenács T, Szoboszlai N, Denkert C, Pete I, Győrffy B.
|
| BMC Cancer 14:837. doi: 10.1186/1471-2407-14-837.
2014
|
| 8 | MAP2K1
|
| Constitutive activation of MEK1 promotes Treg cell instability in vivo.
|
| Guo J, Zhang J, Zhang X, Zhang Z, Wei X, Zhou X.
|
| J Biol Chem 289(51):35139-48. doi: 10.1074/jbc.M114.589192. Epub 2014 Oct 31.
2014
|
| 9 | BRAF, MAP2K1
|
| Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling.
|
| Haling JR, Sudhamsu J, Yen I, Sideris S, Sandoval W, Phung W, Bravo BJ, Giannetti AM, Peck A, Masselot A, Morales T, Smith D, Brandhuber BJ, Hymowitz SG, Malek S.
|
| Cancer Cell 26(3):402-13. doi: 10.1016/j.ccr.2014.07.007. Epub 2014 Aug 21.
2014
|
| 10 | MAP2K1
|
| High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.
|
| Brown NA, Furtado LV, Betz BL, Kiel MJ, Weigelin HC, Lim MS, Elenitoba-Johnson KS.
|
| Blood 124(10):1655-8. doi: 10.1182/blood-2014-05-577361. Epub 2014 Jun 30.
2014
|
| 11 | MAP2K1
|
| Nuclear MEK1 sequesters PPARγ and bisects MEK1/ERK signaling: a non-canonical pathway of retinoic acid inhibition of adipocyte differentiation.
|
| Dave S, Nanduri R, Dkhar HK, Bhagyaraj E, Rao A, Gupta P.
|
| PLoS One 9(6):e100862. doi: 10.1371/journal.pone.0100862. eCollection 2014.
2014
|
| 12 | MAP2K1, PTEN
|
| MEK1 is required for PTEN membrane recruitment, AKT regulation, and the maintenance of peripheral tolerance.
|
| Zmajkovicova K, Jesenberger V, Catalanotti F, Baumgartner C, Reyes G, Baccarini M.
|
| Mol Cell 50(1):43-55. doi: 10.1016/j.molcel.2013.01.037. Epub 2013 Feb 28.
2013
|
| 13 | MAP2K1, MAP2K2, PAK1
|
| p21-activated kinase 1 (PAK1) can promote ERK activation in a kinase-independent manner.
|
| Wang Z, Fu M, Wang L, Liu J, Li Y, Brakebusch C, Mei Q.
|
| J Biol Chem 288(27):20093-9. doi: 10.1074/jbc.M112.426023. Epub 2013 May 7.
2013
|
| 14 | MAP2K1, PKMYT1
|
| MEK1 inactivates Myt1 to regulate Golgi membrane fragmentation and mitotic entry in mammalian cells.
|
| Villeneuve J, Scarpa M, Ortega-Bellido M, Malhotra V.
|
| EMBO J 32(1):72-85. doi: 10.1038/emboj.2012.329. Epub 2012 Dec 14. 2013
|
| 15 | MAP2K1, NCOR2
|
| Nuclear translocation of MEK1 triggers a complex T cell response through the corepressor silencing mediator of retinoid and thyroid hormone receptor.
|
| Guo L, Chen C, Liang Q, Karim MZ, Gorska MM, Alam R.
|
| J Immunol 190(1):159-67. doi: 10.4049/jimmunol.1201657. Epub 2012 Dec 5.
2013
|
| 16 | MAP2K1, RAF1
|
| MEK-1 activates C-Raf through a Ras-independent mechanism.
|
| Leicht DT, Balan V, Zhu J, Kaplun A, Bronisz A, Rana A, Tzivion G.
|
| Biochim Biophys Acta 1833(5):976-86. doi: 10.1016/j.bbamcr.2013.01.015. Epub 2013 Jan 27.
2013
|
| 17 | MAP2k1
|
| MEK1 inhibits cardiac PPARα activity by direct interaction and prevents its nuclear localization.
|
| el Azzouzi H, Leptidis S, Bourajjaj M, van Bilsen M, da Costa Martins PA, De Windt LJ.
|
| PLoS One 7(6):e36799. doi: 10.1371/journal.pone.0036799. Epub 2012 Jun 19.
2012
|
| 18 | MAP2K1, MAPK7, TLR2
|
| ERK5 protein promotes, whereas MEK1 protein differentially regulates, the Toll-like receptor 2 protein-dependent activation of human endothelial cells and monocytes.
|
| Wilhelmsen K, Mesa KR, Lucero J, Xu F, Hellman J.
|
| J Biol Chem 287(32):26478-94. doi: 10.1074/jbc.M112.359489. Epub 2012 Jun 15. 2012
|
| 19 | MAP2K1, MED28
|
| MED28 regulates MEK1-dependent cellular migration in human breast cancer cells.
|
| Huang CY, Chou YH, Hsieh NT, Chen HH, Lee MF.
|
| J Cell Physiol 227(12):3820-7. doi: 10.1002/jcp.24093.
2012
|
| 20 | MAP2K1
|
| Oncogenic MAP2K1 mutations in human epithelial tumors.
|
| Choi YL, Soda M, Ueno T, Hamada T, Haruta H, Yamato A, Fukumura K, Ando M, Kawazu M, Yamashita Y, Mano H.
|
| Carcinogenesis 33(5):956-61. doi: 10.1093/carcin/bgs099. Epub 2012 Feb 10.
2012
|
| 21 | MAP2K1, NEK10
|
| Nek10 mediates G2/M cell cycle arrest and MEK autoactivation in response to UV irradiation.
|
| Moniz LS, Stambolic V.
|
| Mol Cell Biol 31(1):30-42. Epub 2010 Oct 18.
2011
|
| 22 | KSR1, MAP2K1
|
| KSR1 is a functional protein kinase capable of serine autophosphorylation and direct phosphorylation of MEK1.
|
| Goettel JA, Liang D, Hilliard VC, Edelblum KL, Broadus MR, Gould KL, Hanks SK, Polk DB.
|
| Exp Cell Res 317(4):452-63. Epub 2010 Dec 7.
2011
|
| 23 | MAP2K1, MAP2K2
|
| Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.
|
| Nikolaev SI, Rimoldi D, Iseli C, Valsesia A, Robyr D, Gehrig C, Harshman K, Guipponi M, Bukach O, Zoete V, Michielin O, Muehlethaler K, Speiser D, Beckmann JS, Xenarios I, Halazonetis TD, Jongeneel CV, Stevenson BJ, Antonarakis SE.
|
| Nat Genet 44(2):133-9. doi: 10.1038/ng.1026.
2011
|
| 24 | MAP2K1, MAP2K2
|
| MEK2 is sufficient but not necessary for proliferation and anchorage-independent growth of SK-MEL-28 melanoma cells.
|
| Lee CS, Dykema KJ, Hawkins DM, Cherba DM, Webb CP, Furge KA, Duesbery NS.
|
| PLoS One 6(2):e17165. doi: 10.1371/journal.pone.0017165.
2011
|
| 25 | MAP2K1, MAP2K4, MAP3K5, MAPK1, MAPK10, RAF1
|
| How does arrestin assemble MAPKs into a signaling complex?
|
| Song X, Coffa S, Fu H, Gurevich VV.
|
| J Biol Chem 284(1):685-95. Epub 2008 Nov 10. 2009
|
| 26 | CFC, CFC3, CFC4, MAP2K1, MAP2K2
|
| Spectrum of MEK1 and MEK2 gene mutations in cardio-facio-cutaneous syndrome and genotype-phenotype correlations.
|
| Dentici ML, Sarkozy A, Pantaleoni F, Carta C, Lepri F, Ferese R, Cordeddu V, Martinelli S, Briuglia S, Digilio MC, Zampino G, Tartaglia M, Dallapiccola B.
|
| Eur J Hum Genet 17(6):733-40. Epub 2009 Jan 21. 2009
|
| 27 | MAP2K1, MAP2K2
|
| Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal.
|
| Catalanotti F, Reyes G, Jesenberger V, Galabova-Kovacs G, de Matos Simoes R, Carugo O, Baccarini M.
|
| Nat Struct Mol Biol 16(3):294-303. Epub 2009 Feb 15.
2009
|
| 28 | ARRB1, MAP2K1
|
| MEK1 binds directly to betaarrestin1, influencing both its phosphorylation by ERK and the timing of its isoprenaline-stimulated internalization.
|
| Meng D, Lynch MJ, Huston E, Beyermann M, Eichhorst J, Adams DR, Klusmann E, Houslay MD, Baillie GS.
|
| J Biol Chem 284(17):11425-35. Epub 2009 Jan 19.
2009
|
| 29 | HRAS, KRAS, BRAF, CFC2, COSTS, CFC3, MAP2K1, MAP2K2, CFC4, CFC5
|
| Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome.
|
| Schulz AL, Albrecht B, Arici C, van der Burgt I, Buske A, Gillessen-Kaesbach G, Heller R, Horn D, Hbner CA, Korenke GC, Knig R, Kress W, Krger G, Meinecke P, Mcke J, Plecko B, Rossier E, Schinzel A, Schulze A, Seemanova E, Seidel H, Spranger S, Tuysuz B, Uhrig S, Wieczorek D, Kutsche K, Zenker M.
|
| Clin Genet 73(1):62-70. Epub 2007 Nov 27. 2008
|
| 30 | MAP2K1, MAP2K2, BRAF, CFC3, CFC4, CFC2
|
| Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options.
|
| Senawong T, Phuchareon J, Ohara O, McCormick F, Rauen KA, Tetsu O.
|
| Hum Mol Genet 17(3):419-30. Epub 2007 Nov 2. 2008
|
| 31 | BRAF, CFC2, CFC3, CFC4, CFC5, COSTS, HRAS, KRAS, MAP2K1, MAP2K2, NS3
|
| The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders.
|
| Aoki Y, Niihori T, Narumi Y, Kure S, Matsubara Y.
|
| Hum Mutat 29(8):992-1006.
2008
|
| 32 | BRAF, CFC2, CFC3, COSTS, HRAS, KRAS, LEOPS, MAP2K1, MAPK1, MTOR, NF1, NFNS, NS1, NS3, NS4, NS5, PTPN11, RAF1, SOS1
|
| Oncogenes on my mind: ERK and MTOR signaling in cognitive diseases.
|
| Krab LC, Goorden SM, Elgersma Y.
|
| Trends Genet 24(10):498-510. Epub 2008 Sep 4. 2008
|
| 33 | CFC3, CFC4, CFC5, KRAS, MAP2K1, MAP2K2, NS3, NS5, RAF1
|
| Noonan and cardio-facio-cutaneous syndromes: two clinically and genetically overlapping disorders.
|
| Nyström AM, Ekvall S, Berglund E, Björkqvist M, Braathen G, Duchen K, Enell H, Holmberg E, Holmlund U, Olsson-Engman M, Annerén G, Bondeson ML.
|
| J Med Genet 45(8):500-6. Epub 2008 May 2.
2008
|
| 34 | CFC2, CFC3, CFC4, CFC5, KRAS, MAP2K1, MAP2K2, BRAF, COSTS, HRAS
|
| Molecular and clinical characterization of cardio-facio-cutaneous (CFC) syndrome: overlapping clinical manifestations with Costello syndrome.
|
| Narumi Y, Aoki Y, Niihori T, Neri G, Cave H, Verloes A, Nava C, Kavamura MI, Okamoto N, Kurosawa K, Hennekam RC, Wilson LC, Gillessen-Kaesbach G, Wieczorek D, Lapunzina P, Ohashi H, Makita Y, Kondo I, Tsuchiya S, Ito E, Sameshima K, Kato K, Kure S, Matsubara Y.
|
| Am J Med Genet A 143(8):799-807. 2007
|
| 35 | BRAF,CFC2,CFC3,MAP2K1
|
| Further delineation of the phenotype resulting from BRAF or MEK1 germline mutations helps differentiate cardio-facio-cutaneous syndrome from Costello syndrome.
|
| Gripp KW, Lin AE, Nicholson L, Allen W, Cramer A, Jones KL, Kutz W, Peck D, Rebolledo MA, Wheeler PG, Wilson W, Al-Rahawan MM, Stabley DL, Sol-Church K.
|
| Am J Med Genet A 143(13):1472-80. 2007
|
| 36 | CFC2, BRAF, RAF1, MAP2K1, MAP2K2, CFC3, CFC4
|
| Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.
|
| Rodriguez-Viciana P, Tetsu O, Tidyman WE, Estep AL, Conger BA, Cruz MS, McCormick F, Rauen KA.
|
| Science 311(5765):1287-90. Epub 2006 Jan 26. 2006
|
| 37 | CFC2, BRAF, CFC3, MAP2K1, CFC4, MAP2K2, COSTS, HRAS
|
| Distinguishing Costello versus cardio-facio-cutaneous syndrome: BRAF mutations in patients with a Costello phenotype.
|
| Rauen KA.
|
| Am J Med Genet A 140(15):1681-3. No abstract available. 2006
|
| 38 | MAP2K1
|
| Requirement for Map2k1 (Mek1) in extra-embryonic ectoderm during placentogenesis.
|
| Bissonauth V, Roy S, Gravel M, Guillemette S, Charron J.
|
| Development 133(17):3429-40. Epub 2006 Aug 3. 2006
|
| 39 | MAP2K1, MAP2K3, MAP2K4, MAP2K6, MAP2K7, MAP3K1, MAP3K4
|
| Conserved docking site is essential for activation of mammalian MAP kinase kinases by specific MAP kinase kinase kinases.
|
| Takekawa M, Tatebayashi K, Saito H.
|
| Mol Cell 18(3):295-306.
2005
|
| 40 | MAPK1, MAP2K1, MAP2K2
|
| Identification of novel point mutations in ERK2 that selectively disrupt binding to MEK1.
|
| Robinson FL, Whitehurst AW, Raman M, Cobb MH.
|
| J Biol Chem 277(17):14844-52. Epub 2002 Jan 31. 2002
|
| 41 | MAP2K1, MAP2K1P1, MAP2K2
|
| Chromosome mapping of the human genes encoding the MAP kinase kinase MEK1 (MAP2K1) to 15q21 and MEK2 (MAP2K2) to 7q32.
|
| Meloche S, Gopalbhai K, Beatty BG, Scherer SW, Pellerin J.
|
| Cytogenet Cell Genet 88(3-4):249-52. 2000
|
| 42 | MAP2K1
|
| Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo.
|
| Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR, Saltiel AR.
|
| Nat Med 5(7):810-6. 1999
|
| 43 | MAP2K1
|
| Inhibition of the mitogen-activated protein kinase kinase superfamily by a Yersinia effector.
|
| Orth K, Palmer LE, Bao ZQ, Stewart S, Rudolph AE, Bliska JB, Dixon JE.
|
| Science 285(5435):1920-3. 1999
|
| 44 | MAP3K5, MAP2K1, MAP2K3, MAPK4
|
| Chromosomal localization of four MAPK signaling cascade genes : MEK1, MEK3, MEK4 and MEKK5.
|
| Rampoldi L, Zimbello R, Bortoluzzi S, Tiso N, Valle G, Lanfranchi G, Danieli GA.
|
| Cytogenet Cell Genet 78(3-4):301-3. 1997
|
| 45 | MAP2K1
|
| Cytoplasmic localization of mitogen-activated protein kinase kinase directed by its NH2-terminal, leucine-rich short amino acid sequence, which acts as a nuclear export signal.
|
| Fukuda M, et al.
|
| J Biol Chem 271(33):20024-8. 1996
|
| 46 | MAP2K1
|
| The MAPK signaling cascade.
|
| Seger R, Krebs EG.
|
| FASEB J 9(9):726-35. 1995
|
| 47 | MAP2K1
|
| MEKK1 phosphorylates MEK1 and MEK2 but does not cause activation of mitogen-activated protein kinase.
|
| Xu S, Robbins D, Frost J, Dang A, Lange-Carter C, Cobb MH.
|
| Proc Natl Acad Sci U S A 92(15):6808-12.
1995
|
| 48 | MAP2K1, MAP2K2
|
| Cloning and characterization of two distinct human extracellular signal-regulated kinase activator kinases, MEK1 and MEK2.
|
| Zheng CF, Guan KL.
|
| J Biol Chem 268(15):11435-9. 1993
|
| 49 | MAP2K1
|
| Human T-cell mitogen-activated protein kinase kinases are related to yeast signal transduction kinases.
|
| Seger R, Seger D, Lozeman FJ, Ahn NG, Graves LM, Campbell JS, Ericsson L, Harrylock M, Jensen AM, Krebs EG.
|
| J Biol Chem 267(36):25628-31. 1992
|